DBV TECHNOLOGIE/S (DBVT) PT Lowered to $30.00 at Bank of America

DBV TECHNOLOGIE/S (NASDAQ:DBVT) had its price objective trimmed by Bank of America from $33.00 to $30.00 in a research note issued to investors on Friday, November 2nd. The firm currently has a buy rating on the stock.

DBVT has been the topic of a number of other research reports. Zacks Investment Research lowered shares of DBV TECHNOLOGIE/S from a buy rating to a hold rating in a research note on Thursday, September 13th. BidaskClub lowered shares of DBV TECHNOLOGIE/S from a hold rating to a sell rating in a research note on Thursday, October 11th. Morgan Stanley increased their price objective on shares of DBV TECHNOLOGIE/S from $27.00 to $28.00 and gave the stock an equal weight rating in a research note on Friday, July 13th. Finally, Stifel Nicolaus initiated coverage on shares of DBV TECHNOLOGIE/S in a research note on Thursday, September 13th. They set a buy rating and a $35.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $33.67.

Shares of DBV TECHNOLOGIE/S stock traded down $0.80 during trading on Friday, reaching $19.20. The company had a trading volume of 97,222 shares, compared to its average volume of 120,120. The firm has a market cap of $1.14 billion, a PE ratio of -5.70 and a beta of 1.23. DBV TECHNOLOGIE/S has a fifty-two week low of $16.65 and a fifty-two week high of $26.98.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Dynamic Technology Lab Private Ltd acquired a new stake in DBV TECHNOLOGIE/S during the second quarter worth about $285,000. Exane Asset Management raised its stake in DBV TECHNOLOGIE/S by 17.9% during the second quarter. Exane Asset Management now owns 50,000 shares of the company’s stock worth $964,000 after acquiring an additional 7,600 shares during the period. First Midwest Bank Trust Division raised its stake in DBV TECHNOLOGIE/S by 36.7% during the second quarter. First Midwest Bank Trust Division now owns 136,986 shares of the company’s stock worth $2,642,000 after acquiring an additional 36,798 shares during the period. Millennium Management LLC raised its stake in DBV TECHNOLOGIE/S by 842.6% during the first quarter. Millennium Management LLC now owns 133,256 shares of the company’s stock worth $3,074,000 after acquiring an additional 119,119 shares during the period. Finally, BlackRock Inc. raised its stake in DBV TECHNOLOGIE/S by 4.7% during the second quarter. BlackRock Inc. now owns 309,520 shares of the company’s stock worth $5,970,000 after acquiring an additional 14,032 shares during the period. Hedge funds and other institutional investors own 44.65% of the company’s stock.

About DBV TECHNOLOGIE/S

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.

See Also: Beta

Analyst Recommendations for DBV TECHNOLOGIE/S (NASDAQ:DBVT)

Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply